Key result
Pre-interventional soluble ST2 concentrations >10,070 pg/mL were associated with significantly higher 1-year mortality after TAVI compared to lower levels (49.2% vs. 23.2%; OR 3.21; P<0.001).
Why the study?
Does preinterventional soluble ST2 level predict mortality in patients undergoing TAVI?
Cohort (n=274)
Does preinterventional soluble ST2 level predict mortality in patients undergoing TAVI?
Odds Ratio: 3.21 (95% CI 1.7–6.04)
Absolute Event Rate: 49.2% vs 23.2%
p-value: p=<0.001
Elevated preinterventional soluble ST2 levels are strongly associated with increased 1-year mortality after TAVI, suggesting its utility for risk stratification.
Elevated pre-TAVI sST2 may aid mortality risk stratification; leaves open whether it improves selection or warrants prospective validation.
No takes yet. Share an insight, caveat, or question.
Wernly et al. (2016) conducted a cohort in Transcatheter aortic valve implantation (TAVI) (n=274). Soluble ST2 >10,070.27 pg/mL vs. Soluble ST2 ≤10,070.27 pg/mL was evaluated on 1-year mortality (OR 3.21, 95% CI 1.70-6.04, p=<0.001). Pre-interventional soluble ST2 concentrations >10,070 pg/mL were associated with significantly higher 1-year mortality after TAVI compared to lower levels (49.2% vs. 23.2%; OR 3.21; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: